IMU Biosciences

About

IMU Biosciences is a London-based biotechnology company decoding the immune system using high-fidelity multi-omic analysis combined with proprietary machine learning, founded by a team of experimental immunologists and computational biologists with backgrounds at the Francis Crick Institute and King’s College London ¹²³. IMU says it has assembled the world’s largest immune dataset — drawn from more than 25,000 individuals — and can measure over 100 million immune data points from a single blood sample to enable precision medicine ¹². On June 2, 2026, the company announced an oversubscribed Series A extension of more than $53 million (£40 million), bringing its Series A total to over $53M and total funding to about $60 million (£45 million); the round was co-led by IQ Capital and Molten Ventures with support from the British Business Bank, Meltwind, and existing investors ¹²³. Proceeds will fund the company’s Stem Cell Transplant Program, Solid Organ Transplant Program, and MANIFEST — a UK research consortium focused on understanding patient responses to cancer immunotherapies ²³.